Halozyme Appoints Darren Snellgrove as CFO, Formerly of Johnson & Johnson

SEC 8-K Filing Notice

Company: Halozyme Therapeutics, Inc. (HALO) Filing Date: 2026-04-30 Accession Number: 0001159036-26-000053

Items Filed

Item 5.02: Departure of Directors or Certain Officers; Election of Directors Item 9.01: Financial Statements and Exhibits

Summary

Halozyme Therapeutics announced the appointment of Darren Snellgrove as its new Chief Financial Officer, effective June 8, 2026. Snellgrove joins Halozyme from Johnson & Johnson, where he most recently served as Vice President, Investor Relations, and previously as CFO of J&J's Pharmaceutical sector. This strategic hire brings significant financial leadership experience from a major pharmaceutical company to Halozyme, potentially impacting its financial strategy and investor relations. David Ramsay, the current Interim CFO, will transition to an advisory role to assist with the handover.

Key Takeaways

Darren Snellgrove, former VP of Investor Relations and CFO of Pharma at Johnson & Johnson, appointed as Halozyme's CFO effective June 8, 2026.
Snellgrove's compensation includes a $670,000 annual salary, a 50% bonus target, and a minimum $4 million long-term incentive award in 2027.
He will receive $7.2 million in equity awards upon joining, including RSUs and stock options, plus a $350,000 sign-on bonus to offset forgone compensation from J&J.
The appointment signals Halozyme's continued focus on attracting experienced leadership to drive its financial performance and strategic growth.
Interim CFO David Ramsay will transition to an advisory role to ensure a smooth transition.

Analysis

The appointment of Darren Snellgrove as CFO is a significant move for Halozyme. His extensive experience at Johnson & Johnson, particularly in pharmaceutical finance and investor relations, could be invaluable as Halozyme continues to expand its partnered ENHANZE® technology and develop its own pipeline. Investors may view this as a positive sign, indicating Halozyme's commitment to strong financial management and strategic growth. Competitors will likely monitor how Snellgrove's expertise influences Halozyme's financial strategies and business development activities. His background in R&D finance could also signal a renewed focus on internal innovation.

This post was automatically generated from an SEC 8-K filing.